Hearing Stability Following IGF ‐ 1R Inhibitor Treatment in Mice
The Laryngoscope · 16.11.2026
DOI: 10.1002/lary.71063 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 16.11.2026. Verfasst von Christopher Ward und 15 weiteren Autor:innen. Beteiligte Einrichtung: Amgen Inc, Thousand Oaks, California, USA. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Therapeutics.
Abstract (Originalsprache)
Objectives
Teprotumumab is a novel monoclonal antibody treatment for thyroid eye disease that acts through IGF‐1R inhibition. A subset of patients has been reported to experience varying levels of hearing change and other otologic symptoms after therapy. This study aimed to investigate auditory changes following monoclonal antibody IGF‐1R inhibitor treatment in mice.
Methods
Adult CBA/CaJ mice were treated with varying doses of a chimeric IGF‐1R monoclonal antibody (cIGF‐1R mAb), saline, or IgG2a isotype controls ( n = 10 per group) weekly for 20 weeks. Mice underwent auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing at regular intervals. Suprathreshold ABR Wave 1 amplitude growth functions were analyzed at the final timepoint, along with histological assessment of auditory hair cells and presynaptic ribbons. Bodyweight, exposure of cIGF‐1R mAb, and the inhibitory effect of cIGF‐1R mAb in lung tissues were also assessed.
Results
At 20 weeks, there was no significant increase in ABR or DPOAE threshold shift of the experimental cIGF‐1R mAb groups compared with saline controls. No significant decrease in hair cell and presynaptic ribbon counts or suprathreshold ABR Wave 1 amplitude growth functions were observed amongst cIGF‐1R mAb‐treated subjects compared with saline controls. Inhibitory activity of cIGF‐1R mAb was confirmed by the reduced bodyweight gain compared with controls and sustained IGF‐1R pathway inhibition over the study period.
Conclusion
IGF‐1R inhibition in mice shows no consistent electrophysiologic or histological effect on auditory function. Further animal and clinical studies are warranted to evaluate a potential association between IGF‐1R treatment and hearing loss. Level of Evidence N/A
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Amgen Inc, Thousand Oaks, California, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of Iowa, Iowa City, Iowa, USA.
- Paraza Pharma Inc., Montreal, Quebec, Canada.
ORCID-Profile: Marlan R Hansen, Alexander D Claussen
Förderung
- Horizon Therapeutics
Zitieren
APA
Ward, C., Redhage, D., Naanep, C., Salazar, M., Tarabichi, O., Hunger, B., Hossain, M. F., Vaske, A., Alluri, A., Zerrouki, K., Carnevale, G., Lounis, M. A., Kumar, B., Hansen, M. R., Chen, C. R., & Claussen, A. D. (2026). Hearing Stability Following IGF ‐ 1R Inhibitor Treatment in Mice. The Laryngoscope. https://doi.org/10.1002/lary.71063
Vancouver
Ward C, Redhage D, Naanep C, Salazar M, Tarabichi O, Hunger B, et al. Hearing Stability Following IGF ‐ 1R Inhibitor Treatment in Mice. The Laryngoscope. 2026. doi:10.1002/lary.71063
BibTeX
@article{Ward2026,
author = {Ward, Christopher and Redhage, David and Naanep, Caridad and Salazar, Mateo and Tarabichi, Osama and Hunger, Bryce and Hossain, Md Fahad and Vaske, Adam and Alluri, Aditya and Zerrouki, Kamelia and Carnevale, Giustino and Lounis, Mohamed Amine and Kumar, Brajesh and Hansen, Marlan R and Chen, Chang-Rung and Claussen, Alexander D},
title = {Hearing Stability Following IGF ‐ 1R Inhibitor Treatment in Mice},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.71063}
}
EUVIMED